融资融券余额5.64亿元，较昨日上涨0.2%。 证券之星消息，9月22日，润达医疗（603108）融资买入2509.47万元，融资偿还2411.53万元，融资净买 入97.94万元，融资余额5.62亿元，近3个交易日已连续净买入累计1900.25万元。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-09-22 | 97.94万 | 5.62亿 | 5.72% | | 2025-09-19 | 379.44万 | 5.61亿 | 5.58% | | 2025-09-18 | 1422.87万 | 5.57亿 | 5.39% | | 2025-09-17 | -953.26万 | 5.43亿 | 5.32% | | 2025-09-16 | -973.69万 | 5.53亿 | 5.41% | 融券方面，当日融券卖出1.05万股，融券偿还0.0股，融券净卖出1.05万股，融券余量11.6万股。 | 交易日 | 融券冷卖出(股) | | 融券令重(股) | 融券余额(元) | | --- | --- | --- | -- ...

Core Points - The company announced that its stock has met the conditions for the early redemption of "Run Da Convertible Bonds" due to the closing price being at least 130% of the conversion price for at least 15 out of the last 30 trading days from August 25, 2025, to September 17, 2025 [2] - The board of directors has decided not to exercise the early redemption rights for the "Run Da Convertible Bonds" [2]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-051 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于不提前赎回"润达转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司股票自 2025 年 8 月 25 日至 2025 年 9 月 17 日期间，已满足连 续三十个交易日中至少有十五个交易日的收盘价不低于当期转股价格的 130%（含 130%），已触发"润达转债"的赎回条款。公司董事会决定本次 不行使"润达转债"的提前赎回权利，不提前赎回"润达转债"。 未来三个月内（即 2025 年 9 月 18 日至 2025 年 12 月 17 日），如公 司触发"润达转债"的赎回条款均不行使"润达转债"的提前赎回权利。以 2025 年 12 月 17 日之后的首个交易日重新起算，若"润达转债"再次触发赎 回条款，届时公司董事会将再次召开会议决定是否行使"润达转债"的 ...

国金证券股份有限公司 关于上海润达医疗科技股份有限公司 不提前赎回"润达转债"的核查意见 国金证券股份有限公司（以下简称"本保荐机构"）作为上海润达医疗科技 股份有限公司（以下简称"润达医疗"、"公司"）公开发行可转换公司债券的 保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证券交易所上市公 司自律监管指引第12号——可转换公司债券》等相关规定，对润达医疗不提前赎 回"润达转债"事项进行了认真、审慎的核查。核查的具体情况如下： 一、可转债发行上市基本情况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 55,000 万元，发行期限 6 年， 票面利率分别为：第一年 0.3%、第二年 0.6%、第三年 1.0%、第四年 1.5%、第 五年 1.8%、第六年 2.0%。 （二）经上海证券交易所"[2020]185 号"自律监管决定书同意，公司 55,000 万元可转换公司债券于 2020 年 7 月 13 日起在上海证券 ...

Core Viewpoint - Shanghai RunDa Medical Technology Co., Ltd. has triggered the redemption clause for its convertible bonds due to stock price performance but has decided not to exercise this right at this time [1] Group 1: Redemption Clause Trigger - The company's stock has met the condition of closing prices being no less than 130% of the current conversion price for at least 15 out of 30 consecutive trading days from August 25 to September 17, 2025 [1] - The board of directors has decided not to exercise the early redemption right on September 17, 2025, and will also refrain from exercising this right for the next three months, from September 18 to December 17, 2025 [1] Group 2: Future Considerations - After December 17, 2025, if the redemption conditions are met again, the board will make a further decision regarding the redemption [1] - The relevant parties have not held the convertible bonds before the redemption conditions were met and have no plans to reduce their holdings in the next six months [1] Group 3: Convertible Bond Details - The "RunDa Convertible Bonds" were listed on July 13, 2020, with an initial conversion price of 13.36 yuan per share, which has been adjusted to 12.97 yuan per share [1]

关于上海润达医疗科技股份有限公司 2025年第一次临时股东大会的 上海泽昌律师事务所 上海市浦东新区向城路 288 号国华人寿金融大厦 1107A 室 电话：021-61913137 传真：021-61913139 邮编：200122 二〇二五年九月 上海泽昌律师事务所 法律意见书 上海泽昌律师事务所 关于上海润达医疗科技股份有限公司 法律意见书 2025 年第一次临时股东大会的 法律意见书 泽昌证字 2025-01-12-02 致：上海润达医疗科技股份有限公司 上海泽昌律师事务所（以下简称"本所"）接受上海润达医疗科技股份有限公 司（以下简称"公司"）委托，就公司召开 2025 年第一次临时股东大会（以下 简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）中国 证券监督管理委员会发布的《上市公司股东会规则》（以下简称"《股东会规则》"） 等法律、法规、规章和其他规范性文件以及《上海润达医疗科技股份有限公司章 程》（以下简称"《公司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务 ...

上海润达医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-050 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | | 1、出席会议的股东和代理人人数 | 585 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 203,649,582 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 33.7354 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，采用现场及通讯记名投票表决和网络投票 表决相结合的方式召开。公司董事长张诚栩先生主持会议 ...

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - The company Shanghai RunDa Medical Technology Co., Ltd. has issued convertible bonds known as "RunDa Convertible Bonds" with a total issuance amount of 55 million yuan, which were approved by the China Securities Regulatory Commission [2][3] - The bonds have a maturity period of 6 years and a tiered interest rate structure, starting from 0.3% in the first year and reaching 2.0% in the sixth year [2][3] - The initial conversion price for the bonds was set at 13.36 yuan per share, which has been adjusted multiple times due to profit distributions, currently standing at 13.10 yuan per share [3] Group 2 - The company has established conditional redemption terms for the convertible bonds, allowing for redemption if the stock price remains above 130% of the conversion price for at least 15 out of 30 trading days [4][6] - As of the latest update, the company's stock has already met the condition for 10 trading days, and if it continues to meet the criteria, the company may decide to redeem the bonds [6][4] - The redemption will be executed at the face value plus accrued interest, as per the terms outlined in the bond issuance prospectus [4][5]

Core Viewpoint - The case of Dong Hua, former head of the laboratory department at Gong'an County People's Hospital, highlights corruption in the medical procurement sector, involving two listed companies, Dahua Gene and Run Da Medical, with significant financial implications for the industry [1][2][3]. Company Summaries - Dong Hua was sentenced to 10 years in prison for bribery and 6 months for money laundering, with a total fine of 1 million yuan, after accepting bribes totaling 6.5 million yuan from five entities and individuals from 2010 to 2023 [1][2]. - Dahua Gene's regional director, Qiao Peng, and Hu Yingguo, the actual shareholder of Wuhan Run Da, were identified as bribers in the case, with Dahua Gene benefiting from sales of medical equipment and supplies to the hospital [1][3]. - Dahua Gene reported a revenue of 339 million yuan in the first half of 2025, a decrease of 15.44% year-on-year, with a net loss of 182 million yuan, although this represented a significant reduction in losses compared to the previous year [4][5]. - Run Da Medical's first half of 2025 revenue was 3.47 billion yuan, down 16.08% year-on-year, with a net loss of 121 million yuan, reflecting a 232.14% decline compared to the previous year [5]. - Both companies are facing challenges due to intensified competition in the in vitro diagnostics (IVD) industry, driven by ongoing centralized procurement policies and price adjustments, leading to declining demand and prices for testing services [4][5].